The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Intra-patient comparison from larotrectinib clinical trials in TRK fusion cancer: An expanded dataset.
 
David S. Hong
Stock and Other Ownership Interests - MolecularMatch; OncoResponse; Presagia
Consulting or Advisory Role - Acuta; Adaptimmune; Alphasights; Amgen; Axiom Biotechnologies; Baxter; Bayer; Boxer Capital; COG; EcoR1 Capital; Genentech; Gerson Lehrman Group; GroupH; GroupH; Guidepoint Global; H.C. Wainwright & Co.; HCW Precision; Infinity Pharmaceuticals; Infinity Pharmaceuticals; Janssen; Medscape; Merrimack; Numab; Pfizer; Prime Oncology; Seagen; ST Cube; Takeda; Tavistock Life Sciences; Trieza Therapeutics; WebMD; WebMD
Research Funding - Abbvie (Inst); Adaptimmune (Inst); Aldai Norte (Inst); Amgen (Inst); AstraZeneca (Inst); Bayer (Inst); BMS (Inst); Daiichi Sankyo (Inst); Eisai (Inst); Erasca, Inc (Inst); Fate Therapeutics (Inst); Genentech (Inst); Genmab (Inst); Ignyta (Inst); Infinity Pharmaceuticals (Inst); Kite, a Gilead company (Inst); Kyowa (Inst); Lilly (Inst); Loxo (Inst); MedImmune (Inst); Merck (Inst); Mirati Therapeutics (Inst); miRNA Therapeutics (Inst); Molecular Templates (Inst); Mologen (Inst); National Cancer Institute (Inst); Navire (Inst); Novartis (Inst); Numab (Inst); Pfizer (Inst); Seagen (Inst); Takeda (Inst); Turning Point Therapeutics (Inst); Verastem (Inst); VM Pharma (Inst)
Travel, Accommodations, Expenses - AACR; ASCO; Bayer Schering Pharma; Genmab; Loxo; miRNA Therapeutics; Society for Immunotherapy of Cancer
 
Antoine Italiano
Consulting or Advisory Role - Bayer; Daiichi Sankyo; Epizyme; Ipsen; Roche; SpringWorks Therapeutics
Research Funding - AstraZeneca; Bayer; Merck; MSD; Pharmamar; Roche
 
Andrew Briggs
Consulting or Advisory Role - Bayer
 
Jesus Garcia-Foncillas
Consulting or Advisory Role - Abbott; Amgen; Astellas Pharma; AstraZeneca; Bayer; Biocartis; Boehringer Ingelheim; Bristol-Myers Squibb; Celgene; Eisai; Foundation Medicine; GlaxoSmithKline; Hospira; Janssen; Lilly; Loxo; Merck Serono; MSD; Novartis; Pfizer; Pharmamar; Regeneron; Roche; Sanofi; SERVIER; Sysmex; Tesaro
 
Ulrik Niels Lassen
Honoraria - Bayer; Novartis; Pfizer
Consulting or Advisory Role - Bayer; Pfizer
Research Funding - BMS (Inst); GlaxoSmithKline; Pfizer; Roche
 
Gilles Vassal
Consulting or Advisory Role - AstraZeneca; Bayer; Bristol-Myers Squibb; Celgene; Incyte; Ipsen; Lilly; Merck Serono; Novartis; Roche/Genentech; SERVIER; Takeda
Travel, Accommodations, Expenses - Bristol-Myers Squibb; Roche
 
Shivaani Kummar
Stock and Other Ownership Interests - Arxeon Therapeutics (I); PathomIQ
Honoraria - Bayer
Consulting or Advisory Role - Bayer; Boehringer Ingelheim; Cadila Pharmaceuticals (I); Gilead Sciences; Harbour BioMed; MedTree (I); Mundipharma; Seagen; ShangPharma Innovation; SpringWorks Therapeutics
Research Funding - ADC Therapeutics (Inst); Advenchen Laboratories (Inst); Amgen (Inst); Astex Pharmaceuticals (Inst); Bayer (Inst); Bristol-Myers Squibb (Inst); Corvus Pharmaceuticals (Inst); Dynavax Technologies (Inst); Genome & Company (Inst); Incyte (Inst); Jounce Therapeutics (Inst); Loxo (Inst); Moderna Therapeutics (Inst); Pfizer (Inst); Plexxikon (Inst); Seagen (Inst); Taiho Pharmaceutical (Inst)
Travel, Accommodations, Expenses - Bayer
 
Cornelis Martinus van Tilburg
Consulting or Advisory Role - Bayer; Novartis
 
Karen N Keating
Employment - Bayer
 
John A. Reeves
Employment - Bayer
 
Marc Mardoche Fellous
Employment - Bayer
 
Hendrik Nogai
Employment - Bayer
 
Theodore Willis Laetsch
Consulting or Advisory Role - Bayer; Cellectis; Lilly; Loxo; Novartis
Research Funding - Abbvie (Inst); Amgen (Inst); Atara Biotherapeutics (Inst); Bayer (Inst); Bristol-Myers Squibb (Inst); Epizyme (Inst); Foundation Medicine (Inst); GlaxoSmithKline (Inst); Janssen (Inst); Jubilant Pharmaceuticals (Inst); Lilly (Inst); Loxo (Inst); Merck Sharp & Dohme (Inst); Novartis (Inst); Novella Clinical (Inst); Pfizer (Inst); SERVIER (Inst)
 
Alexander E. Drilon
Honoraria - Foundation Medicine; Medscape; MORE Health; OncLive; Peerview; PeerVoice; Physicans' Education Resource; Research to Practice; Targeted Oncology
Consulting or Advisory Role - 14ner Oncology/Elevation Oncology; Abbvie; Archer; AstraZeneca; Bayer; BeiGene; BerGenBio; Blueprint Medicines; EMD Serono/Merck; Exelixis; Genentech/Roche; Helsinn Therapeutics; Hengrui Therapeutics; Ignyta; Lilly; Loxo; Melendi; Monopteros Therapeutics; Monopteros Therapeutics; MORE Health; Novartis; Pfizer; Remedica; Repare Therapeutics; Takeda/Millennium; TP Therapeutics; Tyra Biosciences; Verastem; Verastem
Research Funding - Foundation Medicine
Patents, Royalties, Other Intellectual Property - Wolters Kluwer (Royalties for Pocket Oncology)
Other Relationship - GlaxoSmithKline; Merck; Pfizer; PharmaMar; Puma Biotechnology; Taiho Pharmaceutical; Teva